Cytokinetics CEO exercises options, sells 7,500 shares
Robert I. Blum, President & CEO of Cytokinetics, exercised 7,500 stock options at $10.60 per share into common stock on July 27, 2026 and sold 7,500 shares at $80.87 per share, pursuant to a Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Robert I. Blum, President & CEO of Cytokinetics, exercised 7,500 stock options at $10.60 per share into common stock on July 27, 2026 and sold 7,500 shares at $80.87 per share, pursuant to a Rule 10b5-1 trading plan. Following the option exercise, 179,245 options of this type remain directly held. The filing also reports indirect holdings of 2,083 shares in each of The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($527K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Blum Robert I
Role
President & CEO
Sold
7,500 shs ($607K)
Approx. gross sale proceeds
$607K
Approx. exercise cost
$80K
Approx. pre-tax spread
$527K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,500 | $10.60 | $80K |
| Sale | Common Stock | 7,500 | $80.87 | $607K |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 179,245 contracts (Direct);
Common Stock — 377,820 shares (Direct);
Common Stock — 2,083 shares (Indirect, by Trust 1);
Common Stock — 2,083 shares (Indirect, by Trust 2)
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Key Figures
Options exercised: 7,500 shares
Exercise price: $10.60 per share
Shares sold: 7,500 shares
+4 more
7 metrics
Options exercised
7,500 shares
Non-Qualified Stock Options exercised into common stock on July 27, 2026
Exercise price
$10.60 per share
Conversion or exercise price of options exercised on July 27, 2026
Shares sold
7,500 shares
Common stock sold on July 27, 2026 at $80.87 per share
Sale price
$80.87 per share
Price per share for 7,500 Cytokinetics common shares sold
Options remaining
179,245 options
Non-Qualified Stock Options remaining directly held after the reported exercise
Bridget trust holdings
2,083 shares
Common stock held indirectly by The Bridget Blum 2003 Irrevocable Trust
Brittany trust holdings
2,083 shares
Common stock held indirectly by The Brittany Blum 2003 Irrevocable Trust
Key Terms
Non-Qualified Stock Option, Exercise or conversion of derivative security, Rule 10b5-1 trading plan, Irrevocable Trust
4 terms
Non-Qualified Stock Option financial
"Security title lists Non-Qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Exercise or conversion of derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security"
Rule 10b5-1 trading plan regulatory
"A document-level checkbox affirms trades under a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Irrevocable Trust financial
"Footnotes state shares held by The Bridget Blum 2003 Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cytokinetics (CYTK) CEO Robert Blum report?
Robert Blum reported exercising 7,500 stock options at $10.60 per share and selling 7,500 Cytokinetics (CYTK) shares at $80.87 per share. These transactions occurred on July 27, 2026 and were reported together as an exercise-and-sell sequence.
At what price were Robert Blum’s Cytokinetics (CYTK) stock options exercised?
The reported Cytokinetics (CYTK) stock options were exercised at an exercise price of $10.60 per share. This exercise converted 7,500 Non-Qualified Stock Options into common stock before a same-day sale of those shares at a higher market price.
How many Cytokinetics (CYTK) stock options does Robert Blum still hold after the transaction?
After exercising 7,500 options, Robert Blum is reported as holding 179,245 Non-Qualified Stock Options of this type. This figure reflects his remaining derivative position from that option grant as of the July 27, 2026 transaction date.
Were the Cytokinetics (CYTK) insider trades made under a Rule 10b5-1 plan?
Yes. The filing’s Rule 10b5-1 checkbox indicates the Cytokinetics (CYTK) transactions were made under a Rule 10b5-1 trading plan. Such plans prearrange trade timing and size, which can reduce the informational content of the trade’s specific execution date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
